Host-microbiota relationship in the pathophysiology of aseptic abscess syndrome: protocol for a multicentre case-control study (ABSCESSBIOT).
IMMUNOLOGY
INTERNAL MEDICINE
Inflammatory bowel disease
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
04 08 2023
04 08 2023
Historique:
medline:
7
8
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
Aseptic abscess (AA) syndrome is a rare disease whose pathophysiology is unknown. It is often associated with inflammatory bowel disease and characterised by sterile inflammation with collections of neutrophils affecting several organs, especially the spleen. Microbiota are known to influence local and systemic immune responses, and both gut and oral microbiota perturbations have been reported in diseases associated with AA syndrome. However, interactions between these factors have never been studied in AA syndrome. The purpose of this translational case-control study (ABSCESSBIOT) is to investigate gut and/or oral microbiota in patients with AA syndrome compared with healthy controls. Moreover, microbiota associated metabolites quantification and Treg/Th17 balance characterisation will give a mechanistic insight on how microbiota may be involved in the pathophysiology of AA syndrome. This French multicentre case-control study including 30 French centres (University hospital or regional hospital) aims to prospectively enrol 30 patients with AA syndrome with 30 matched controls and to analyse microbiota profiling (in stools and saliva), microbial metabolites quantification in stools and circulating CD4 This study protocol was reviewed and approved by an independent French regional review board (n° 2017-A03499-44, Comité de Protection des Personnes Ile de France 1) on 10 October 2022, and declared to the competent French authority (Agence Nationale de Sécurité du Médicament et des produits de santé, France). Oral and written informed consent will be obtained from each included patient and the control participant. Study results will be reported to the scientific community at conferences and in peer-reviewed scientific journals. Clinical Trials web-based platform (NCT05537909).
Identifiants
pubmed: 37541750
pii: bmjopen-2023-073776
doi: 10.1136/bmjopen-2023-073776
pmc: PMC10407381
doi:
Banques de données
ClinicalTrials.gov
['NCT05537909']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e073776Investigateurs
Felix Ackermann
(F)
Romain Altwegg
(R)
Elisabeth Aslangul
(E)
Alexandra Audemard-Verger
(A)
Fairouzé Bani Sadr
(F)
Sophie Besnard
(S)
Fabrice Bonnet
(F)
Jean-David Bouaziz
(JD)
Jean-François Bourgaux
(JF)
Guillaume Cadiot
(G)
Olivier Chosidow
(O)
Jerome Connault
(J)
Nathalie Costedoat-Chalumeau
(N)
Sebastien De Almeida
(S)
Amandine Dernoncourt
(A)
Hélène Desmurs Clavel
(H)
Amelie Dutheil
(A)
Stanislas Faguer
(S)
Jean-Marc Galempoix
(JM)
Arnaud Hot
(A)
Camille Hua
(C)
Estelle Jean
(E)
Patrick Jego
(P)
Wendy Jourde
(W)
Clemence Lepelletier
(C)
François Lifermann
(F)
Nicolas Limal
(N)
Alexandre Thibault Jacques Maria
(ATJ)
Jean Benoit Monfort
(JB)
Maria Nachury
(M)
Yves Poinsignon
(Y)
Marie Laure Rabilloux
(ML)
Jerome Razatomaery
(J)
Clea Rouillon
(C)
Mihaela Saplacan
(M)
Jean Schmidt
(J)
Laure Swiader
(L)
Laurent Sailler
(L)
Jean-François Viallard
(JF)
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Gut Microbes. 2021 Jan-Dec;13(1):1968257
pubmed: 34494943
Medicine (Baltimore). 2007 May;86(3):145-161
pubmed: 17505254
Inflamm Bowel Dis. 2011 Jan;17(1):179-84
pubmed: 20839241
Nat Commun. 2022 Oct 3;13(1):5820
pubmed: 36192482
Front Immunol. 2020 Feb 27;11:166
pubmed: 32174910
Science. 2012 Jun 8;336(6086):1268-73
pubmed: 22674334
Nat Rev Immunol. 2013 May;13(5):321-35
pubmed: 23618829
Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):S56-S63
pubmed: 27156371
Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E791-800
pubmed: 26811460
J Crohns Colitis. 2018 Jan 24;12(2):204-216
pubmed: 29373727
J Sep Sci. 2012 Aug;35(15):1906-13
pubmed: 22865755
Cell. 2009 Oct 30;139(3):485-98
pubmed: 19836068
Immunity. 2014 Aug 21;41(2):311-24
pubmed: 25088769
Gut. 2013 Apr;62(4):531-9
pubmed: 22993202
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Dig Dis Sci. 2008 Feb;53(2):490-9
pubmed: 17570063
Immunity. 2012 Jan 27;36(1):92-104
pubmed: 22177117
Clin Immunol. 2015 Aug;159(2):122-127
pubmed: 26141651
Appl Environ Microbiol. 2005 Jul;71(7):3692-700
pubmed: 16000778
Ann Pathol. 1999 Sep;19(4):294-8
pubmed: 10544764
ISME J. 2012 Aug;6(8):1621-4
pubmed: 22402401
Am J Gastroenterol. 1995 Jul;90(7):1183-4
pubmed: 7611230
Nature. 2020 Jan;577(7790):410-415
pubmed: 31875848
Front Pediatr. 2021 Jan 21;8:620254
pubmed: 33553076
Appl Environ Microbiol. 2018 Jan 31;84(4):
pubmed: 29196292
Autoimmun Rev. 2015 Apr;14(4):269-76
pubmed: 25435420
Talanta. 2019 Apr 1;195:593-598
pubmed: 30625588
Nature. 2011 Oct 26;479(7374):538-41
pubmed: 22031325
J Clin Med. 2022 Jun 25;11(13):
pubmed: 35806955
Scand J Gastroenterol. 2011 May;46(5):577-82
pubmed: 21114433
Clin Rheumatol. 2016 Jun;35(6):1437-41
pubmed: 27075462
Immunity. 2010 Jun 25;32(6):815-27
pubmed: 20620945
J Autoimmun. 2013 Aug;44:21-33
pubmed: 23810578
Gut. 2009 Aug;58(8):1152-67
pubmed: 19592695
Mod Rheumatol. 2014 Jan;24(1):217-9
pubmed: 24261782
Nat Med. 2019 Apr;25(4):701
pubmed: 30846883